BRIDGED HETEROCYCLYL-SUBSTITUTED PYRIMIDINE COMPOUNDS, PREPARATION METHOD AND MEDICAL USE THEREOF - THE NAT INSTITUTES OF PHARMACEUTICAL R&D CO LTD

Title:

BRIDGED HETEROCYCLYL-SUBSTITUTED PYRIMIDINE COMPOUNDS, PREPARATION METHOD AND MEDICAL USE THEREOF

Document Type and Number:

WIPO Patent Application WO/2022/152140

Kind Code:

A1

Abstract:

Bridged heterocyclyl-substituted pyrimidine compounds, a preparation method and medical use thereof. The compounds or pharmaceutical compositions comprising same can be used as JAK1 and TYK2 kinase inhibitors for treating JAK1 and TYK2 kinase activity-related diseases such as inflammations, autoimmune diseases and cancers.

More Like This:

JP2002535314	INDUSTRIAL APPLICABILITY A compound that inhibits leukocyte adhesion mediated by VLA-4.
JP6409004	N-substituted 5-substituted phthalamic acid as a saltyrin inhibitor
JP5628427	How to prepare rosuvastatin calcium intermediate

Inventors:

YIN HUIJUN (CN)
YAN XU (CN)
SHI JIZHOU (CN)
LIU GUOBIAO (CN)
DONG LIUXIN (CN)
SHAO MINGZHAO (CN)

Application Number:

PCT/CN2022/071491

Publication Date:

July 21, 2022

Filing Date:

January 12, 2022

Export Citation:

Click for automatic bibliography generation Help

Assignee:

THE NAT INSTITUTES OF PHARMACEUTICAL R&D CO LTD (CN)

International Classes:

C07D239/42; A61K31/506; A61P37/00; C07D403/12

Domestic Patent References:

WO2021027647A1

2021-02-18

Foreign References:

CN107074867A	2017-08-18
CN110862376A	2020-03-06
CN113372351A	2021-09-10

Other References:

ANDREW FENSOME, CATHERINE M. AMBLER, ERIC ARNOLD, MARY ELLEN BANKER, MATTHEW F. BROWN, JILL CHRENCIK, JAMES D. CLARK, MARTIN E. DO: "Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S )-2,2-Difluorocyclopropyl)((1 R ,5 S )-3-(2-((1-methyl-1 H -pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 61, no. 19, 11 October 2018 (2018-10-11), US , pages 8597 - 8612, XP055688622, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.8b00917
J. IMMUNOL., vol. 194, 2015, pages 21
J. MED. CHEM., vol. 57, 2014, pages 5023
J MED CHEM, vol. 61, 2018, pages 8597 - 8612

Attorney, Agent or Firm:

GE CHENG & CO., LTD (CN)

Download PDF:

View/Download PDF PDF Help

Previous Patent: MULTI-BEAM LENS ANTENNA AND ACTIVE LENS ANTENNA SYSTEM

Next Patent: POLYMER CONJUGATED LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS